argenex (NASDAQ:ARGX) Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded argenx from “Buy” to “Hold,” although broader analyst sentiment remains positive with a “Moderate Buy” consensus and an average price target of $1,142.37.
• argenx reported quarterly earnings of $7.80 per share, beating estimates of $7.44, while revenue reached $1.75 billion; analysts expect full-year EPS of $25.79.
• ARGX opened at $873.71, with a market capitalization of approximately $54.95 billion and a 52-week range of $661.85 to $1,072.75. Institutional investors own about 60.32% of the shares.

argenex (NASDAQ:ARGX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

ARGX has been the topic of a number of other research reports. Wells Fargo & Company lowered their target price on argenex from $1,356.00 to $1,336.00 and set an "overweight" rating on the stock in a research note on Friday. HC Wainwright raised their target price on argenex from $940.00 to $1,202.00 and gave the stock a "buy" rating in a report on Tuesday, August 18th. DZ Bank reiterated a "buy" rating on shares of argenex in a research report on Friday, October 9th. Oppenheimer decreased their price target on argenex from $1,100.00 to $1,038.00 and set an "outperform" rating for the company in a report on Monday, October 12th. Finally, Truist Financial upped their price objective on argenex from $1,030.00 to $1,095.00 and gave the stock a "buy" rating in a research report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $1,142.37.

argenex Price Performance

NASDAQ ARGX opened at $873.71 on Friday. argenex has a 1 year low of $661.85 and a 1 year high of $1,072.75. The company has a market capitalization of $54.95 billion, a PE ratio of 30.49, a P/E/G ratio of 0.79 and a beta of 0.44. The company has a fifty day moving average of $956.62 and a 200 day moving average of $885.37.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, topping the consensus estimate of $7.44 by $0.36. The company had revenue of $1.75 billion for the quarter. argenex had a return on equity of 35.77% and a net margin of 31.66%. Research analysts expect that argenex will post 25.79 earnings per share for the current year.

Hedge Funds Weigh In On argenex

A number of institutional investors have recently bought and sold shares of the company. Tidal Investments LLC grew its holdings in shares of argenex by 97.8% during the 2nd quarter. Tidal Investments LLC now owns 2,362 shares of the company's stock worth $2,191,000 after purchasing an additional 1,168 shares during the period. Squarepoint Ops LLC raised its holdings in argenex by 314.8% in the 2nd quarter. Squarepoint Ops LLC now owns 58,400 shares of the company's stock valued at $54,182,000 after buying an additional 44,321 shares during the period. Peregrine Capital Management LLC purchased a new stake in argenex in the 2nd quarter valued at about $27,584,000. Optiver Holding B.V. raised its holdings in argenex by 907.0% in the 1st quarter. Optiver Holding B.V. now owns 10,110 shares of the company's stock valued at $7,383,000 after buying an additional 9,106 shares during the period. Finally, Janus Henderson Group PLC lifted its position in argenex by 3.4% in the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company's stock valued at $1,847,592,000 after buying an additional 83,568 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Strong quarterly results: argenx reported $7.80 in EPS, exceeding the $7.44 consensus estimate, while revenue reached $1.75 billion. Product net sales grew 54% year over year to $1.7 billion, and operating profit was $486 million. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Bullish analyst support: Morgan Stanley raised its price target from $1,140 to $1,190 and maintained an “overweight” rating. Wells Fargo also maintained “overweight” despite trimming its target from $1,356 to $1,336. Jefferies called the post-news setup a potentially attractive entry point. Morgan Stanley rating
• Neutral Sentiment: Targets remain above the market price, but revisions are mixed: Guggenheim lowered its target from $1,185 to $1,120 while keeping a “buy” rating. Robert W. Baird raised its target from $823 to $861 but retained a “neutral” rating, and RBC reportedly cut its target. These changes suggest continued confidence in long-term value but more cautious near-term expectations. Guggenheim rating
• Negative Sentiment: Clinical-development setback is overshadowing the earnings beat: Reports highlighted a surprise testing setback for argenx’s core drug, raising concerns about future growth, product expansion and execution. That issue appears to be driving the weaker investor reaction despite the company’s strong sales and profitability. argenx testing setback

About argenex

argenx SE NASDAQ: ARGX is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx's lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.